Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

This randomized, open-label, exploratory trial investigates the impact of teriparatide administration timing by comparing subcutaneous injection at 08:00 versus 20:00 on bone turnover markers in postmenopausal women with osteoporosis.

Why It Was Studied

Accumulating evidence highlights the critical role of circadian rhythms in regulating bone turnover.

Bone turnover markers, including parathyroid hormone, C-terminal telopeptide of type I collagen, and N-terminal propeptide of type I procollagen, all exhibit distinct diurnal variations.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Teriparatide study did not mask who received what.

The primary outcomes are the between-group differences in serum parathyroid hormone, C-terminal telopeptide of type I collagen, and N-terminal propeptide of type I procollagen profiles, which will be assessed at baseline, 4 weeks, and 12 weeks.

Secondary outcomes will evaluate the safety profile during the trial.

What Was Measured

Topics PubMed links to this paper include Teriparatide, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Circadian Rhythm, Parathyroid Hormone, Biomarkers and Bone Remodeling.

The authors tagged it with the keywords Bone turnover markers, Postmenopausal osteoporosis and Timing.

What This Means in Plain Language

The paper is a randomized and open-label study of Teriparatide.

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Journal of orthopaedic surgery and research), a journal based in England.

More context: the Teriparatide compound page, all human trials.